54 results about "Enkephalin" patented technology

A compound is provided that has the formula

NH₂CH₂CH₂CH₂C(O)N—R   (I)

where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidetransferrin, glucosylamnine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

A compound is provided that has the formula

NH₂CH₂CH₂CHR¹C(O)N—R  (I)

where R¹ is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosylamine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

A method for skin antiaging treatment including administering Botulinum toxin to an area of facial and/or neck skin, combined with the administration of a cosmetic or pharmaceutical composition having a cosmetically or pharmaceutically effective amount of at least one peptide derived from the SNAP-25 protein and/or at least one enkephalin-derived peptide, and at least one cosmetically or pharmaceutically acceptable excipient or adjuvant.

A compound provided by the present invention includes an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently bonded to a biologically active peptide. One example of an inventive compound described is a conjugate of an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently coupled to an opioid peptide, such as an endorphin, enkephalin, dynorphin or endomorphin. Also detailed are processes for making the described conjugates and pharmaceutical compositions including such compounds.

The present invention provides a pharmaceutical composition that includes a) one or both of i) a peptide ligand that binds a zeta receptor and ii) at least one cancer chemotherapeutic agent; and b) a sustained release formulation. The invention also provides a combination including at least a portion of a tissue comprising one or more cells harboring a zeta receptor, such as a cancer cell or a precancerous cell, in contact with a pharmaceutical composition of the invention. Additionally the invention provides a method of treating a pathology that responds to a peptide ligand that binds a zeta receptor that includes a step of contacting a tissue characteristic of the pathology and containing cells harboring a zeta receptor, with a pharmaceutical composition of the invention. The invention further provides methods of inhibiting proliferation or metastasis of a cancer in a subject, including a) surgically excising a tumor characterizing the cancer from the subject; b) ensuring maximal removal of a tumor margin from the tumor site; and c) disposing a pharmaceutical composition of the invention upon a tissue remaining at a tumor margin wherein the tissue contains one or more tumor cells (such as a cancer cell or a precancerous cell) harboring a zeta receptor. The peptide ligand of a zeta receptor may be an enkephalin, an endorphin, a dynorphin, or a derivative thereof. Additionally the pharmaceutical composition may include one or more cancer chemotherapeutic agents.

The invention discloses polyethylene glycol derivatives of an enkephalin analogue, a preparation method, and a composition containing the same. The polyethylene glycol derivatives of an enkephalin analogue of the invention comprises an enkephalin analogue and polyethylene glycol covalently connected to a C end of the enkephalin analogue, wherein the enkephalin analogue has the following structure: X-Try-Y1-Gly-Phe-Y2-Y3-Z, and X is H or Ac; Y1 is D-Ala or Gly; Y2 is D-Ala or Met or Leu; Y3 is Cys or high Cys or Lys or Arg or His, and is a residue modified by PEG; Z is OH or NH2. The polyethylene glycol derivatives of the enkephalin analogue provided by the invention can be used to prepare analgesic drugs or precursor compounds of the drugs.

The invention discloses a low-frequency therapeutic apparatus for drug detoxification, which is regulated and controlled by a computer and is equipment for the drug detoxification and solves the problem of poor effects of healing with drugs for the drug detoxification in the past. The low-frequency therapeutic apparatus for the drug detoxification, regulated and controlled by the computer, comprises a power source and a shell, the shell is internally provided with a controller and the input end of the controller is connected with the computer while the output end of the controller is connected with a therapeutic electrode. By virtue a method of acupuncture points and meridians in the traditional Chinese medical science, a pulse signal generated by the driving of the controller by the computer passes through the therapeutic electrode and a skin electric shocking pulse is directly adopted to stimulate acupuncture points of a human body for treatment, thus promoting the releasing of enkephalin in the human body, further relieving the withdrawal symptoms of opiate narcotics and having the effects of pain easing and spasmolysis and better withdrawal effect than amidone methadone. The therapeutic apparatus of the invention has safe and reliable application, no pain, no side effect, and obvious effects for relieving addiction and controlling relapse. The computer is used for regulating and controlling so as to realize simple operation and accurate curative effect.

The invention belongs to the technical field of treating tumor by adopting an immunization therapy method, and particularly relates to application of naloxone or hydrochloride thereof or composition of the naloxone or the hydrochloride thereof with methionine enkephalin in preparing a drug for treating cancer. The application of the naloxone in preparing the drug for treating the cancer is characterized in that the naloxone and the hydrochloride thereof or the composition of the naloxone and the hydrochloride thereof and the methionine enkephalin are applied to preparing the drug for treating the cancer. The drug can be prepared into tablets, capsules, spraying agent, aerosol and eye drops. The application aims to fill the blank on the research of treating the cancer by using the naloxone and the hydrochloride thereof or/and the composition of the naloxone and the hydrochloride thereof and the methionine enkephalin.

Disclosed are a method and a corresponding pharmaceutical composition for treating damaged ligaments. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of ligaments damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).

A topical opioid paradigm was developed to determine analgesic peripheral effects of morphine. Topical morphine as well as peptides such as [D-Ala2,MePhe4,Gly(ol)5]enkephalin (DAMGO) produced a potent, dose-dependent analgesia using the radiant heat tailflick assay. The topical drugs potentiated systemic agents, similar to the previously established synergy between peripheral and central sites of action. Local tolerance was rapidly produced by repeated daily topical exposure to morphine. Topical morphine tolerance was effectively blocked by the N-Methyl-D-Aspartate (NMDA) receptors antagonist MK801 and ketamine given either systemically or topically. NMDA receptor antagonists reversed pre-existing morphine tolerance. The activity of topical NMDA antagonists to block local morphine tolerance suggests that peripheral NMDA receptors mediate topical morphine tolerance. Morphine was cross tolerant to [D-Ala2,MePhe4,Gly(ol)5]enkephalin (DAMGO), but not to morphine-6 beta -glucuronide, implying different mechanisms of action. These observations have great importance in the design and use of opioids clinically. Topical pharmaceutical compositions comprising an analgesic that functions through an opiate receptor and an NMDA receptor antagonist for producing analgesia without inducing tolerance are described.

The invention relates to the technical field of disinfection products, in particular to a cloud rose aromatherapy disinfection spray and a preparation method thereof. The cloud rose aromatherapy disinfection spray is prepared from the following components in parts by weight: 94 to 96 parts of rosa damascena flower water, 2 to 3 parts of a compound quaternary ammonium salt, 2 to 3 parts of grapefruit extract, 5 to 10 parts of common vladimiria root volatile oil, 5 to 10 parts of an emulsifier and 1000 parts of water. The rosa damascena flower water and the composite quaternary ammonium salt areadded, the aromatherapy effect is good while disinfection and sterilization are conducted, the rose water is pleasant in fragrance and fragrant in smell, after natural aromatic hydrocarbon enters thebrain from olfactory nerves, frontal lobes of the brain can be stimulated to secrete two hormones of endorphin and enkephalin, and the spirit is in the most comfortable state; and the rose water andthe grapefruit extract also have good soothing and nourishing effects on the skin.

The invention discloses an acupoint electrical stimulation method and an acupoint electrical stimulation device for auxiliary treatment of inflammatory pain. The acupoint electrical stimulation method is characterized by outputting a bidirectional symmetric rectangular pulse current with output frequency of 2/120Hz, when the frequency is 2Hz, the wave width is 400mu s, when the frequency is 120Hz, the wave width is 100mu s, and sparse waves and dense waves each last 3 seconds, thereby achieving pain alleviation for inflammatory pain. The device for implementing the acupoint electrical stimulation method comprises a pulse generator and electrodes. The acupoint electrical stimulation method and the acupoint electrical stimulation device can obviously increase the secretion of central nerve endogenous enkephalin and beta-endorphin, inhibits generation of peripheral IL-1beta, has anti-inflammatory and pain alleviating effects, is conductive to alleviating the inflammatory pain, offers intelligent operation for a patient to relieve pain by using an instrument on his own, and can improve life quality of patients with pain.